CompanyCNTXNasdaqPhiladelphia, PA

Context Therapeutics Inc.

Context Therapeutics develops T cell-engaging bispecific antibodies for solid tumors.

SEC EDGAR ClinicalTrials.gov

424B3Sep 10Latest SEC filing

Jul 21Latest story

July 2026

Context Therapeutics posts results for terminated elacestrant-onapristone breast cancer trial

Jul 21Trial updateContext Therapeutics Inc.elacestrant

Results posted for onapristone-anastrozole trial in refractory endometrial cancer

Jul 17Trial updateanastrozole Context Therapeutics Inc.